At the J.P. Morgan Healthcare Conference that took place this week in San Francisco, California, Republic of Korea-based biotech company Celltrion announced that it is preparing to build a new overseas production plant that will add to the strength of its biosimilar program.
At the J.P. Morgan Healthcare Conference that took place this week in San Francisco, California, Republic of Korea-based biotech company Celltrion announced that it is preparing to build a new overseas production plant that will add to the strength of its biosimilar program.
The new plant, with a production capacity of 360,000 liters, is triple the capacity of what Celltrion had initially planned. This decision was made to “ensure stable supplies as well as leverage on economy of scale to further lower the prices of its biosimilar drugs,” said Celltrion’s CEO, Jung Jin Seo.
The company currently owns 2 other production plants that, when running at full capacity, are capable of 50,000 liters and 90,000 liters, respectively.
During Seo’s presentation, he compared Celltrion to major global pharmaceutical companies such as Amgen and Genentech. Currently, Celltrion has 2 biosimilars on the market: infliximab (marketed as Inflectra in the United States, and referenced on Remicade), and rituximab (marketed as Truxima in the European Union, referenced on Rituxan).
Celltrion is also in the process of carrying out clinical trials of adalimumab (based on AbbVie’s Humira) and bevacizumab (based on Genentech’s Avastin) biosimilars. In order to create a competitive edge, the company says that it plans to develop its adalimumab biosimilar as a high-concentrate formula which enables a smaller injection volume than is currently on the market.
For its bevacizumab biosimilar, the company expects to be the first on a global scale to bring a bevacizumab biosimilar to the market, kicking off sales with a “first-mover advantage,” said Seo. However, there some biosimilar developers are further along than Celltrion in their bevacizumab programs. In November 2017, Indian drug maker Biocon announced that it launched a bevacizumab biosimilar in India. In addition, Amgen’s biosimilar, Mvasi, received FDA approval last year, though it has not yet been marketed.
Also in Celltrion’s pipeline is a subcutaneous-administration version of infliximab, which is not yet available in the market, as well as cetuximab (referenced on Erbitux) to treat colorectal cancer, and palivizumab (referenced on Synagis), which has a major indication for respiratory diseases.
Looking to the future, Celltrion is interested in potentially investing in the medical device business; as Seo reports, Celltrion sees big opportunities in both telemedicine and the next-generation diagnostics market. In the years ahead, “the firm plans to make strategic investments in these businesses,” said Seo.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.